SCHEMBL23988608

SCHEMBL23988608

C=CC(=O)Nc1cccc(NS(=O)(=O)c2cccc(C(C)C)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 2/20 0.47
TEK Q02763 2/20 0.47
KDR P35968 1/20 0.47
PGR P06401 1/20 0.47
PKM P14618 2/20 0.46
CA2 P00918 1/20 0.46
TGM2 P21980 3/20 0.46
BTK Q06187 3/20 0.45
IDH2 P48735 1/20 0.45
PIK3CD O00329 1/20 0.45
AURKA O14965 1/20 0.45
PIK3C2G O75747 1/20 0.45
PIK3CG P48736 1/20 0.45
AURKB Q96GD4 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.42
FBP1 P09467 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988607 0.92 PGR (0.54) EPHB4TEKKDRPGRPKM
SCHEMBL23988635 0.89 BTK (0.52) PGRPKMTGM2BTKLMNA
SCHEMBL20885030 0.86 LMNA (0.57) EPHB4TEKKDRCA2TGM2
SCHEMBL9568677 0.83 TGM2 (0.58) PKMTGM2BTKAURKAAURKB
SCHEMBL17660300 0.83 EPHB4 (0.61) EPHB4TEKKDRCA2TGM2
SCHEMBL23988636 0.81 EGFR (0.49) PKMTGM2BTKIDH2PIK3CD
SCHEMBL9568796 0.81 TGM2 (0.58) PGRPKMTGM2MEN1KMT2A
SCHEMBL20885062 0.81 TGM2 (0.55) EPHB4TEKKDRCA2TGM2
SCHEMBL9568733 0.80 BTK (0.63) CA2TGM2BTKPIK3CDAURKA
SCHEMBL23988609 0.80 BTK (0.47) CA2TGM2BTKPIK3CDPIK3C2G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11155556-B2 Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155556-B2 Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders PI4KA, PIK3CA, PI4KB EPHB4 1972/4885TEK 1762/4885KDR 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.